Literature DB >> 30456546

Protective effect of astaxanthin against contrast-induced acute kidney injury via SIRT1-p53 pathway in rats.

Dongmei Gao1, Hu Wang1, Yang Xu1, Di Zheng2, Quan Zhang2, Wenhua Li3,4.   

Abstract

PURPOSE: The present study was designed to further investigate the protective effect of astaxanthin (AST) on contrast-induced acute kidney injury (CI-AKI) in rats and the relationship between SIRT1-p53 pathway and astaxanthin.
METHODS: 40 adult male Sprague Dawley (SD) rats were randomly divided into five groups (n = 8/group): control (CON), normal rats treated with AST (AST), CM-treated (CM), CM rats treated with isoform of nitric oxide synthase (iNOS) inhibitor (iNOS + CM), and CM rats treated with AST (AST + CM). Serum creatinine (Scr) and blood urea nitrogen (BUN) values were measured at 72 h following the procedure. Hematoxylin and eosin (H-E) staining was used to observe the pathologic changes of kidney. Tunel staining was used to test apoptosis of kidney tubules. Oxidative stress, SIRT1 activity, nitric oxide (NO), and 3-nitrotyrosine (3-NT) content were individually measured with the commercial available kits.
RESULTS: Compared with the CON group, Scr and BUN levels significantly increased in the CM group (P < 0.05), and the values in two pre-treatment groups (iNOS + CM and AST + CM) had significantly decreased (P < 0.05). H-E and Tunel staining had shown that renal tubular injury was severe in CM group. The renal injury score and apoptosis index in the two pre-treatment groups also decreased (P < 0.05). The present study showed that in CM group the levels of oxidative stress indicators significantly increased, and the activities of antioxidant stress indicators significantly decreased. These indicators in two pre-treatment groups significantly improved (P < 0.05). In the CM group the expression levels of SITR1 significantly increased, and the ac-p53/p53 significantly increased (P < 0.05). Compared with the CM group, in AST + CM group the expression levels of SIRT1 increased, the expression levels of p53 and ac-p53/p53 decreased (P < 0.05).The levels of NO and 3-NT in CM group significantly increased (P < 0.05). Compared the CM group, the levels in the two pre-treatment groups significantly decreased (P < 0.05).
CONCLUSIONS: Astaxanthin has a protective effect on CI-AKI, the mechanism may be related to the SIRT1-p53 pathway. Astaxanthin can reduce the content of NO and 3-NT in renal tissue of CI-AKI, and alleviate the renal injury induced by contrast agents.

Entities:  

Keywords:  3-NT; Acute kidney injury; Apoptosis; Astaxanthin; Oxidative stress; SIRT1-p53 pathway

Mesh:

Substances:

Year:  2018        PMID: 30456546     DOI: 10.1007/s11255-018-2027-2

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  27 in total

1.  Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion.

Authors:  Naohiro Terada; Takashi Hamazaki; Masahiro Oka; Masanori Hoki; Diana M Mastalerz; Yuka Nakano; Edwin M Meyer; Laurence Morel; Bryon E Petersen; Edward W Scott
Journal:  Nature       Date:  2002-03-13       Impact factor: 49.962

2.  Novel astaxanthin prodrug (CDX-085) attenuates thrombosis in a mouse model.

Authors:  Sanjoy K Khan; Tadeusz Malinski; R Preston Mason; Ruslan Kubant; Robert F Jacob; Kazutoshi Fujioka; Scott J Denstaedt; Timothy J King; Henry L Jackson; A David Hieber; Samuel F Lockwood; Thomas H Goodin; Fredric J Pashkow; Peter F Bodary
Journal:  Thromb Res       Date:  2010-08-21       Impact factor: 3.944

Review 3.  Sirtuins and their relevance to the kidney.

Authors:  Chuan-Ming Hao; Volker H Haase
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

4.  Effect of contrast-induced nephropathy on cardiac outcomes after use of nonionic isosmolar contrast media during coronary procedure.

Authors:  Jae Yeong Cho; Myung Ho Jeong; Su Hwan Park; In Soo Kim; Keun Ho Park; Doo Sun Sim; Nam Sik Yoon; Hyun Ju Yoon; Hyung Wook Park; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Cardiol       Date:  2010-08-13       Impact factor: 3.159

5.  Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation.

Authors:  S Chung; B-S Shin; E Hedlund; J Pruszak; A Ferree; Un Jung Kang; Ole Isacson; Kwang-Soo Kim
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

6.  Kidney-specific overexpression of Sirt1 protects against acute kidney injury by retaining peroxisome function.

Authors:  Kazuhiro Hasegawa; Shu Wakino; Kyoko Yoshioka; Satoru Tatematsu; Yoshikazu Hara; Hitoshi Minakuchi; Keiko Sueyasu; Naoki Washida; Hirobumi Tokuyama; Maty Tzukerman; Karl Skorecki; Koichi Hayashi; Hiroshi Itoh
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

7.  Background fluctuation of kidney function versus contrast-induced nephrotoxicity.

Authors:  Richard J Bruce; Aji Djamali; Kazuhiko Shinki; Steven J Michel; Jason P Fine; Myron A Pozniak
Journal:  AJR Am J Roentgenol       Date:  2009-03       Impact factor: 3.959

8.  Malnutrition and inflammation in acute kidney injury due to earthquake-related crush syndrome.

Authors:  Gui-Sen Li; Xiu-Ling Chen; Yuan Zhang; Qiang He; Fang Wang; Da-Qing Hong; Ping Zhang; Lei Pu; Yue Zhang; Xiu-Chuan Yang; Li Wang
Journal:  BMC Nephrol       Date:  2010-03-27       Impact factor: 2.388

9.  Asialoerythropoietin prevents contrast-induced nephropathy.

Authors:  Yukiyo Yokomaku; Toshiro Sugimoto; Shinji Kume; Shin-ichi Araki; Keiji Isshiki; Masami Chin-Kanasaki; Masayoshi Sakaguchi; Norihisa Nitta; Masakazu Haneda; Daisuke Koya; Takashi Uzu; Atsunori Kashiwagi
Journal:  J Am Soc Nephrol       Date:  2008-01-09       Impact factor: 10.121

10.  SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts.

Authors:  Jing Huang; Qini Gan; Limin Han; Jian Li; Hai Zhang; Ying Sun; Zongyu Zhang; Tanjun Tong
Journal:  PLoS One       Date:  2008-03-05       Impact factor: 3.240

View more
  7 in total

1.  Is it possible to prevent contrast-induced nephropathy with dexpanthenol?

Authors:  Osman Sutcuoglu; Mehmet Kursat Derici; Ozge Tugce Pasaoglu; Burak Dumludag; Ozant Helvacı; Betul Ogut; Ipek Isık Gonul; Ulver Derici
Journal:  Int Urol Nephrol       Date:  2019-06-11       Impact factor: 2.370

Review 2.  Activators of SIRT1 in the kidney and protective effects of SIRT1 during acute kidney injury (AKI) (effect of SIRT1 activators on acute kidney injury).

Authors:  Alireza Raji-Amirhasani; Mohammad Khaksari; Fatemeh Darvishzadeh Mahani; Zahra Hajializadeh
Journal:  Clin Exp Nephrol       Date:  2021-03-29       Impact factor: 2.801

Review 3.  Astaxanthin as a Putative Geroprotector: Molecular Basis and Focus on Brain Aging.

Authors:  Vincenzo Sorrenti; Sergio Davinelli; Giovanni Scapagnini; Bradley J Willcox; Richard C Allsopp; Donald C Willcox
Journal:  Mar Drugs       Date:  2020-07-05       Impact factor: 5.118

Review 4.  TUNEL Assay: A Powerful Tool for Kidney Injury Evaluation.

Authors:  Christopher L Moore; Alena V Savenka; Alexei G Basnakian
Journal:  Int J Mol Sci       Date:  2021-01-02       Impact factor: 5.923

5.  Impact of Dietary Modifications on Plasma Sirtuins 1, 3 and 5 in Older Overweight Individuals Undergoing 12-Weeks of Circuit Training.

Authors:  Paulina Wasserfurth; Josefine Nebl; Miriam Rebekka Rühling; Hadeel Shammas; Jolanthe Bednarczyk; Karsten Koehler; Tim Konstantin Boßlau; Karsten Krüger; Andreas Hahn; Anibh Martin Das
Journal:  Nutrients       Date:  2021-10-27       Impact factor: 5.717

Review 6.  Astaxanthin and its Effects in Inflammatory Responses and Inflammation-Associated Diseases: Recent Advances and Future Directions.

Authors:  Ming Xian Chang; Fan Xiong
Journal:  Molecules       Date:  2020-11-16       Impact factor: 4.411

Review 7.  The Pathophysiology and the Management of Radiocontrast-Induced Nephropathy.

Authors:  Eunjung Cho; Gang-Jee Ko
Journal:  Diagnostics (Basel)       Date:  2022-01-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.